九安醫療(002432.SZ):美國子公司已收到1.908億美元全額合同價款
格隆匯5月28日丨九安醫療(002432.SZ)公佈,公司子公司iHealth Labs Inc.(以下簡稱“美國子公司”)和美國DLA(Defense
Logistics Agency)代表美國HHS(Department of Health and Human
Services)於美國時間2022年11月22日簽訂了《採購合同》(以下簡稱“合同”),向其銷售7,200萬人份iHealth試劑盒產品,合同價税合計金額為1.908億美元(含運費)。
截至本公吿日,公司美國子公司已經履行完成上述合同的交貨義務,並收到了上述1.908億美元全額合同價款,上述合同履行完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.